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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYAdvances in the scalable production of blood cells from induced pluripotent stem cells (iPSCs) open prospects for the clinical translation
of de novo generated blood products, and evoke the need for preclinical evaluation of their efficacy, safety, and immunogenicity in large
animalmodels. Due to substantial similarities with humans, the outcomes of cellular therapies in non-human primate (NHP)models can
be readily extrapolated to a clinical setting. However, the use of this model is hampered by relatively low efficiency of blood generation
and lack of lymphoid potential in NHP-iPSC differentiation cultures. Here, we generated transgene-free iPSCs from different NHP species
and showed the efficient induction of mesoderm, myeloid, and lymphoid cells from these iPSCs using a GSK3b inhibitor. Overall, our
studies enable scalable production of hematopoietic progenitors from NHP-iPSCs, and lay the foundation for preclinical testing of
iPSC-based therapies for blood and immune system diseases in an NHP model.INTRODUCTION
Induced pluripotent stem cells (iPSCs) have created novel
opportunities for the scalable manufacture of blood
products for clinical use. Recent advances in hematopoi-
etic differentiation from human pluripotent stem cells
have brought the clinical translation of iPSC-derived
blood products close to reality. Further progression re-
quires proof-of-concept animal studies in addition to
preclinical safety and toxicity assessment of stem cell
therapies in animal models. Due to the significant
differences in hematopoietic system homeostasis, cell sur-
face markers, major histocompatibility complex (MHC)
antigens, requirements for engraftment of hematopoietic
cells (Harding et al., 2013; Trobridge and Kiem, 2010),
and short life span, rodent models have a limited value
for assessing the immunogenicity and safety of iPSC-
derived therapies. Because humans and non-human pri-
mates (NHPs) share similar hematopoietic stem cell
(HSC) dynamics, homing, and engraftment properties
(reviewed in Trobridge and Kiem, 2010), orthologous
MHC genes (Adams and Parham, 2001), and a very similar
killer cell immunoglobulin-like receptor (KIR) structure
and organization (Bimber et al., 2008; Parham et al.,
2010), NHPs will be the most appropriate model to
address the therapeutic efficacy and immunogenicity of
allogeneic blood products. In addition, NHP models areStem Cecritical for evaluating the long-term safety of stem cell
therapies.
However, the use of an NHP model is hampered by the
limited availability of clinically relevant NHP-iPSC lines.
While themajority of NHP-iPSCs described in the literature
were generated using retroviral vectors, human iPSCs in-
tended for eventual therapeutic use need to be generated
using transgene-free technologies. In addition, the effi-
ciency of hematopoietic differentiation from NHP PSCs re-
mains relatively low, and generation of lymphoid cells
from them represents a significant challenge (Gori et al.,
2012, 2015; Hiroyama et al., 2006; Shinoda et al., 2007;
Umeda et al., 2004, 2006). Here, we describe generation
of clinically relevant transgene-free iPSCs from different
NHP species, including rhesus, Chinese cynomolgus, and
Mauritian cynomolgus monkeys, and demonstrate that
GSK3b inhibition is essential to induce rapid and efficient
differentiation of the NHP-iPSCs into multipotential he-
matopoietic progenitors. NHP-iPSC-derived hematopoietic
progenitors were capable of differentiating further into
mature cell types of myeloid and lymphoid lineages,
including natural killer (NK) and T cells. The kinetics and
hierarchy of hematopoietic differentiation from NHP-
iPSCs was similar to those of human PSCs. Overall, these
studies lay the foundation for advancing an NHP model
for preclinical testing of iPSC-based therapies for blood
diseases.ll Reports j Vol. 6 j 243–256 j February 9, 2016 j ª2016 The Authors 243
RESULTS
Generation and Characterization of iPSCs from
Rhesus, Chinese Cynomologus, and Mauritian
Cynomologus Macaques
Primate fibroblasts were generated from skin punches of
rhesus, Chinese cynomologus, and Mauritian macaques,
then reprogrammed into iPSCs using EBNA/OriP-based
episomal plasmids (Yu et al., 2009). Three to four weeks
following electroporation of fibroblasts, iPSC colonies
morphologically similar to both human and NHP embry-
onic stem cells (ESCs) began to appear. A subset of these
colonies was picked and expanded on mouse embryonic
fibroblasts (MEFs) and then transitioned to vitronectin-
coated plates, where they were further expanded and char-
acterized. iPSCs from all three NHP species grew as colonies
morphologically similar to NHP ESCs and expressed the
pluripotency factors OCT4, NANOG, and SOX2 (Figures
S1A, S1B, 1A, and 1B). In addition, NHP-iPSCs stained pos-
itive for alkaline phosphatase similarly to ESCs (Figures 1B
and S1A), formed teratomas following injection into the
hind leg of SCID-beige mice (Figures 1C and S1C), and
maintained a normal karyotype (Figure 1D). PCR analysis
of iPSCs confirmed that they no longer contained the
episomal reprogramming plasmids (Figure S1D). The estab-
lished RhF5 iPS 19.1 line from rhesus macaque, the
ChCy.F.3L iPS line from Chinese cynomolgus macaque,
and theMnCy0669 iPS#1 line fromMauritian cynomolgus
macaque were used for subsequent hematopoietic differen-
tiation studies.GSK3b Inhibition Promotes Mesoderm and Blood
Formation from NHP-iPSCs
Previously, we established an OP9 co-culture system for
the efficient differentiation of human PSCs, including
iPSCs and ESCs (Choi et al., 2009a, 2009b; Vodyanik
et al., 2005; Vodyanik and Slukvin, 2007). However, mul-
tiple attempts to apply this differentiation system to
NHP-iPSCs failed to produce robust hematopoiesis. Anal-
ysis of expression of the mesodermal marker APLNR
(D’Aniello et al., 2009; Vodyanik et al., 2010; Yu et al.,
2012) in differentiation cultures revealed that inefficient
hematopoiesis from NHP-iPSCs in OP9 co-cultures could
be related to impaired induction of mesoderm, especially
in cynomolgus iPSC cultures (Figure 2A). Thus, we tried
to improve hematopoiesis by supplementing OP9 co-
cultures with known factors that support mesoderm
formation and hematopoietic specification from PSCs,
including BMP4, basic fibroblast growth factor (bFGF), ac-
tivin A, and vascular endothelial growth factor (VEGF).
Although we observed an increase in CD34+ and the for-
mation of a limited number of CD45+ cells following244 Stem Cell Reports j Vol. 6 j 243–256 j February 9, 2016 j ª2016 The Auaddition of VEGF, other factors had a negligible effect
on hematopoiesis (Figure S2A).
Since the Wnt pathway has been shown to play a role
in the induction of mesoderm and definitive hematopoi-
esis (Davis et al., 2008; Mendjan et al., 2014; Nostro
et al., 2008; Sturgeon et al., 2014; Sumi et al., 2008), we
tested whether mesoderm formation from NHP-iPSCs
could be enhanced by using the GSK-3 inhibitor
CHIR99021, a known Wnt agonist (Polychronopoulos
et al., 2004). A dose-analysis study revealed that treat-
ment with 4 mM of CHIR99021 on days 1 and 2 of
differentiation coupled with continuous treatment with
50 ng/ml VEGF was optimal for the induction of CD45+
hematopoietic cells and APLNR+ mesoderm (Figures 2A,
2B, and S2B). The efficient induction of mesoderm in
the presence of CHIR99021 was confirmed using qPCR.
As shown in Figure 2C, CHIR99021-treated iPSCs from
different NHP species expressed significantly higher levels
of T and KDR mesodermal genes shortly after CHIR
treatment.
Using CHIR and VEGF, we were able to induce blood pro-
duction from rhesus, Chinese cynomolgus, and Mauritian
cynomolgus monkey iPSCs (Figure 2D). The addition of
stem cell factor (SCF), thrombopoietin (TPO) interleukin-3,
(IL-3), and IL-6 hematopoietic cytokines further improved
the output of hematopoietic progenitors in our differentia-
tion system. When total cells were collected from differen-
tiation cultures, the percentage of CD34+CD45+ cells from
different primate species was approximately 20%–30%
(Figure 2D). As in humans (Choi et al., 2009a; Vodyanik
et al., 2006), the majority of hematopoietic progenitors
induced from NHP-iPSCs co-expressed CD43 and CD31
(Figure 2D). Kinetic analysis of differentiation in OP9 co-
cultures with CHIR99021 reveals striking similarities in he-
matopoietic differentiation between human iPSCs and
NHP-iPSCs. Similar to human iPSC differentiation on
OP9 (Vodyanik et al., 2005), the first hematoendothelial
markers CD34 and CD31, were detected on day 4–5 fol-
lowed by CD45, whose expression could be detected by
day 8 (Figure S3A).
Based on this, we established the optimal differentiation
protocol depicted in Figure 3A. To simplify the enrichment
of hematopoietic progenitors, we collected only floating
cells which became abundant at day 10 of differentiation
of iPSCs in co-cultures with OP9. Flow cytometric analysis
of day 10 floating cells revealed that more than 90% of
them have the CD34+CD45+CD31+CD38CD45RA
phenotype of multipotent hematopoietic progenitors (Fig-
ure 3B). In addition, the majority (>70%) of floating cells
were CD90+. Typically, we were able to produce 2–3 3
106 CD34+CD45+ floating cells from 106 iPSCs (Table 1).
The attached fraction mainly consisted of CD34+CD31+
CD43CD45 endothelial cells (approximately 40%) andthors
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Figure 1. Generation and Characterization of Primate iPSCs
(A) Expression of pluripotency markers in RHF5-iPS 19.1 from rhesus, MnCy0669 iPS #1 from Mauritian cynomolgus, and ChCy.F3L from
Chinese cynomolgus monkey iPSCs. ChCy.F.3L iPS photographs show colonies stained with mouse OCT3/4 and rabbit SOX2 antibodies
followed by donkey anti-mouse Alexa Fluor 568 and donkey anti-rabbit Alexa Fluor 488 (upper and lower rows) and colonies stained with
rabbit NANOG antibodies followed by anti-rabbit Alexa Fluor 488 (middle row). MnCy0669 iPS#1 and RhF5 iPS 19.1 photographs show
colonies stained with mouse OCT3/4 and rabbit NANOG antibodies followed by donkey anti-mouse Alexa Fluor 568 and donkey anti-rabbit
Alexa Fluor 488 (upper and middle rows) and colonies stained with rabbit SOX2 antibodies followed by anti-rabbit Alexa Fluor 488 (lower
row). Scale bar represents 400 mm.
(B) Expression of alkaline phosphatase in NHP-iPSC lines. Scale bar represents 400 mm.
(C) Teratomas from the indicated NHP-iPSCs show derivatives of all three embryonic germline layers, including cartilage (mesoderm),
retinal pigmented epithelium or keratinocytes (ectoderm), and gut-like structures (endoderm).
(D) Karyotypes of the generated NHP-iPSCs.
See also Figure S1.
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residual OP9 cells, with less than 2% being CD45+ and
CD43+ hematopoietic cells (Figure S4A).
Next, we assessed the hematopoietic potential of cells
collected on day 10 of differentiation using a colony-form-
ing unit assay (CFU assay). In these studies, we used serum-
containing MethoCult H4435 design for the detection of
hematopoietic colonies from human somatic CD34+ cells.
The NHP-iPSC lines from all tested NHP species formed col-
onies in semisolid medium mainly consisting of CFU-M
(-macrophage), CFU-GM (-granulocyte macrophage), and
CFU-G (-granulocyte) (Figure 3C). The number of colonies
was near 400–600 per 105 plated cells (Figure 3D), which is
at least 8-fold higher than that reported for NHP ESCs and
iPSCs (Abed et al., 2015; Gori et al., 2012, 2015; Shinoda
et al., 2007; Umeda et al., 2006), and slightly less than
the CFU numbers produced by rhesus cord blood CD34+
cells. In total, we were able to generate 3.9–5.5 3 103 CFU
from 106 iPSCs (Table 1). However, we observed a relatively
higher proportion of CFU-M and CFU-G and a relatively
lower proportion of multipotent CFU-GM and GEMM
(granulocytes, erythrocytes, monocytes/macrophages,
megakaryocytes) in iPSC-derived CD34+CD45+ cells
compared with cord blood CD34+ cells (Figure 3D). Despite
the abundance of myeloid colonies in differentiation cul-
ture, we failed to detect a substantial number of erythroid
colonies. Although we were able to improve detection of
CFU-E from differentiated iPSCs by reducing fetal bovine
serum to 10% in MethoCult, the number of erythroid col-
onies remained consistently low (Figure 3D). Kinetic anal-
ysis of the CFU potential during differentiation revealed
that CFU-E were the first to appear at day 4 of differentia-
tion followed by CFU-M on day 5, while both CFU-G and
CFU-GM appeared on day 7 (Figure S3B). These kinetics
resemble that of hematopoietic CFUs in human cultures
(Vodyanik et al., 2005). Themajority of colony-forming ac-
tivity was found within the floating cell fraction, whereas
the attached fraction generated a much lower number of
colonies, most of which were CFU-M (Figure S4B).
To confirm that our differentiation protocol induces effi-
cient blood formation from a broad range ofNHP PSC lines,
including NHP ESCs, we applied our protocol to induce he-
matopoietic differentiation from rhesus ESCs, R366.4 andFigure 2. GSK3b Inhibition Promotes Mesoderm Formation and E
(A) Effect of CHIR99021 and VEGF on the expression of APLNR on day
(B) ChCy.F.3L iPSCs in OP9 co-culture were treated with indicated d
amounts of CD45-positive cells were measured on day 10 by flow cyto
(C) The effect of 2 days of CHIR99021 treatment on the expression
expression normalized to ACTB is shown. Error bars denote mean ± SE
(D) Effect of hematopoietic cytokines on blood production from NHP-
OP9 with CHIR and VEGF with or without hematopoietic cytokines,
following collection of total cultures.
See also Figure S2.
Stem CeR456. We, along with others, have previously reported
that these cells produce mostly endothelial cells and very
few (<1%) hematopoietic cells in conventional OP9 and
embryoid body differentiation systems (Kaufman et al.,
2004; Rajesh et al., 2007). Using our differentiation proto-
col with CHIR99021, we were able to induce a 17-fold
higher production of CD34+CD45+ hematopoietic progen-
itors from these rhesus ESCs (Figure S4C) compared with
prior studies. The number of colonies formed from rhesus
ESCs in CFU assay was very similar to the number of
colonies formed from differentiated NHP-iPSCs (about
500 per 105 plated cells; Figure S4D).
Recently, we developed chemically defined conditions
for inducing hematopoiesis from human iPSCs (Uenishi
et al., 2014). This protocol eliminates the variations associ-
ated with the use of xenogeneic feeder cells and serum.
Although we failed to induce differentiation from NHP-
iPSCs using the defined conditions described for human
cells (Uenishi et al., 2014), the addition of CHIR99021 dur-
ing the initial 2 days of differentiation in this system
allowed for CD34+CD45+ hematopoietic progenitor forma-
tion and CFUs (Figures S4E and S4F), although hematopoi-
etic differentiation of NHP-iPSCs in the defined systemwas
less efficient when compared with OP9 co-culture. Thus,
our findings indicate that GSK3b inhibition successfully
allows for the induction of blood formation from a broad
range of NHP PSCs, and could be applied to various differ-
entiation protocols.
Differentiation of NHP-iPSCs toward Mature Cells of
Myeloid Lineages
To confirm the potential of the day-10 hematopoietic pro-
genitors to generate mature blood cells, we collected the
floating cells, consisting mainly of CD34+CD45+ double-
positive cells, and replated them on OP9 in differentiation
medium containing 50 ng/ml SCF, 20 ng/ml TPO, 20 ng/ml
IL-3, 20 ng/ml IL-6, and 0.5 U/ml erythropoietin (Fig-
ure 4A). Cytospins of the floating cells 3 days after replating
showed abundant nucleated erythroid cells, granulocytes,
and macrophages (Figure 4B). These findings were consis-
tent among all tested NHP-iPSCs from different primate
species. Interestingly, we observed numerous red bloodfficient Hematopoiesis
4 of differentiation of indicated iPSC lines in co-culture with OP9.
oses of CHIR99021 along with 50 ng/ml VEGF for 2 days, and the
metry.
of T and KDR mesodermal genes as measured by qRT-PCR. Relative
from at least three experiments (*p < 0.01, **p < 0.001).
iPSCs. iPSC lines from different NHP species were differentiated on
and were analyzed on day 10 of differentiation by flow cytometry
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Table 1. Yield of Hematopoietic Cells from 1 3 106 iPSCsa
iPSCs
CD45+CD34+
Cells (3106) CFU (3103)
Red Blood
Cells (3106)
Myeloid
Cells (3106)
CD4+CD8+
T Cells (3106) NK Cells (3106)
MnCy0669 iPS#1 3.1 ± 0.2 3.9 ± 1.4 33.3 ± 8.8 12.7 ± 1.8 12.3 ± 1.4 3.5 ± 0.8
ChCy.F.3L iPS 2.8 ± 0.2 5.5 ± 2.7 17.7 ± 6.2 22.3 ± 1.5 10.7 ± 0.9 2.7 ± 0.6
RhF5 iPS 19.1 2.0 ± 0.2 5.1 ± 5.5 7.3 ± 0.9 8.1 ± 0.04 8.2 ± 0.4 1.0 ± 0.1
aData shown are mean ± SE from three independent experiments.cells in expansion cultures, despite relatively low CFU-E
counts. Thus, we concluded that the low level of CFU-E is
most likely an experimental artifact due to suboptimal con-
ditions for their detection in a semisolid medium, rather
than a reflection of an actual limited erythroid potential
of hematopoietic cells generated from NHP-iPSCs. To
confirm our conclusion and evaluate whether we can use
our differentiation system to produce mature erythroid
cells, we transferred day-10 hematopoietic progenitors
onto OP9 and cultured them in the presence of TPO, SCF,
and erythropoietin for an additional 7 days. As shown in
Figure 4C, cultures of CD34+CD45+ cells in these condi-
tions generated an almost pure population of CD71+
CD45 red blood cells, most of which were enucleated.
Typically, our cultures generated 1–2 3 107 red blood cells
from 106 iPSCs (Table 1). Hemoglobin analysis by qRT-PCR
revealed that erythroid cells during the early stages of
expansion predominantly expressed embryonic 3- and fetal
g-hemoglobins with some adult b-hemoglobin (Figures
S5A and S5B). However, as the expansion of these cells
continues, 3-hemoglobin expression decreased while the
expression of b-hemoglobin significantly increased, and
at day 21 of differentiation the level of b-hemoglobin
expression in erythroid cultures reached or exceeded its
level in fetal liver and bonemarrowmononuclear cells (Fig-
ures S5A and S5B).
To demonstrate megakaryocytic potential, we cultured
day-10 floating cells with SCF, TPO, IL-3, IL-6, and IL-11
in feeder-free conditions. As shown in Figure 4C, these cul-
ture conditions generated megakaryocytic cells expressing
CD41a and CD42a. Finally, we confirmed the potential ofFigure 3. Characterization of Hematopoiesis Induced in the Pres
(A) Schematic representation of the established differentiation pr
NHP-iPSCs.
(B) Phenotype of floating cells collected from MnCy0669#1 iPSC/OP9
(C) CFU potential of the floating cells. Microscopic images show colony
for CFU assay represents 200 mm and that for cytospins is 50 mm. G
E, erythroid.
(D) Graphs display the frequency of colony-forming units (left) and th
(right). Error bars denote mean ± SE from at least three experiments
See also Figures S3 and S4.
Stem Ceday-10 CD34+CD45+ cells to generate mature myelomono-
cytic cells by culturing them in the presence of GM-colony
stimulating factor (GM-CSF) (Figure 4C). These myeloid
cultures yielded 0.8–2.2 3 107 myelomonocytic cells
from 106 iPSCs (Table 1).
Differentiation of NHP-iPSCs toward Lymphoid
Lineages
As reported by the Keller group (Sturgeon et al., 2014), acti-
vation of b-catenin pathways using GSK3b inhibitor is crit-
ical for the generation of definitive hematopoietic cells
with lymphoid potential from human PSCs. To find out
whether GSK3b inhibition supports specification of he-
matopoietic progenitors with T lymphoid potential, we
collected CD45+ floating cells from day-10 differentiated
cultures and replated them onto OP9 expressing DLL4
(OP9-DLL4) (Kennedy et al., 2012; Timmermans et al.,
2009; Uenishi et al., 2014) as depicted in Figure 5A. By
week 3, CD4+CD8+ double-positive T cells arose, which
were also CD5+CD7+. In addition, we detected approxi-
mately 10% of CD3+TCRab+ double-positive cells in our
T cell differentiation cultures (Figure 5B). We were typically
able to obtain 8–12 3 106 of CD4+CD8+ cells from 106
iPSCs (Table 1). PCR analysis revealed greater expression
levels of the RAG1 and RAG2 genes that are involved in
the initiation of V(D)J recombination during B and T cell
development in iPSC-derived Tcells comparedwith periph-
eral blood Tcells. Levels of CD3E expression were similar in
T cells generated from iPSCs and isolated from peripheral
blood (Figure 5C). To confirm T cell development, we
analyzed the genomic DNA of the hematopoietic cellsence of GSK3b Inhibitor
otocol for induction of mesoderm and blood formation for the
co-culture on day 10 of differentiation.
morphology (upper panels) and cytospins (lower panels). Scale bar
, granulocytes; M, macrophages; GM, granulocytes/macrophages;
e relative proportion of the different types of colony-forming units
.
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from OP9-DLL4 cultures for the presence of T cell receptor
(TCR) rearrangements. This analysis demonstrated the
presence of multiple PCR products of random V-J and D-J
rearrangements at the b locus and V-J rearrangements at
the g locus, indicative of a polyclonal T lineage repertoire
(Figure 5D).
To differentiate NK cells, floating cells from OP9 co-cul-
ture day 10 were isolated and cultured on confluent OP9-
hDLL4 in the presence of IL-7, Flt3 ligand, and IL-2.Within
approximately 2 weeks of the culture, lysis of OP9-hDLL4
stromal cells was observed. Flow cytometric analysis at
4 weeks using CD159a, a highly specific marker for NHP
NK cells (Mavilio et al., 2005), along with CD56, confirmed
the presence of NK cells in culture (Figure 5E). Similarly to
peripheral blood NKs, iPSC-derived NK cells expressed
PRF1 perforin and IFNG genes (Figure 5F). Using our differ-
entiation protocol we were able to obtain 1–3.5 3 106 NK
cells from 1 3 106 iPSCs (Table 1).DISCUSSION
This study presents a successful generation of transgene-
free iPSCs from different primate species including rhesus,
Chinese cynomolgus, andMauritian cynomolgusmonkeys
using episomal vectors. The access to transgene-free NHP-
iPSCs is critical for establishing clinically relevant large
animal models that use cells analogous to human cells in-
tended for clinical trials. In addition, we showed that
GSK3b inhibition allows for the efficient production of he-
matopoietic progenitors with both myeloid and lymphoid
potentials from NHP-iPSCs.
Several protocols have been described for the induction
of hematopoietic differentiation from NHP-iPSCs. These
protocols employed co-culture of monkey cells with OP9
or other feeders and an embryoid body method (Abed
et al., 2015; Gori et al., 2012, 2015; Hiroyama et al., 2006;
Shinoda et al., 2007; Umeda et al., 2004, 2006). However,
these studies reported the generation up to 5% CD34+
CD45+ hematopoietic progenitors and up to 75 CFU per
105 cells in total cultures. In our studies, we demonstrated
that the addition ofGSK3b inhibitor potentiatesmesodermFigure 4. Generation of Mature Blood Cells from Day-10 CD34+CD
(A) Schematic representation of the protocol followed for the producti
hematopoietic progenitors derived from iPSCs in co-culture with OP9
(B) Floating cells were collected on day-10 iPSC/OP9 co-culture, transf
SCF, TPO, IL-3, IL-6, and erythropoietin. Cytospins of day-3 culture
including erythroid (E), granulocytes (G), monocytes/macrophages (M
depicts the relative proportion of blood cells in cytospins.
(C) Directed differentiation of day-10 CD34+CD45+ floating cells to ery
and flow cytometry plots are shown. Scale bar represents 50 mm.
See also Figure S5.
Stem Ceinduction fromNHP-iPSCs and increases the efficacy of clo-
nogenic blood progenitor generation from NHP-iPSCs at
least 10-fold, compared with previously published studies.
In addition, hematopoietic commitment and differentia-
tion in our system proceeded more rapidly, approximately
within 6–10 days, compared with 15 or more days in other
studies. Thus, our system simplifies the manufacture of
blood cells for preclinical studies. Importantly, our differ-
entiation system induces progenitors with T and NK cell
lymphoid potentials. Overall, we were able to generate
greater than 23 106 CD34+CD45+ multipotential hemato-
poietic progenitors containing greater than 4 3 103 CFU
from 1 3 106 NHP-iPSCs in our differentiation system
(Table 1). Recent studies have demonstrated hematopoietic
engraftment in NOD/SCID/IL-2 receptor g-chain-null mice
following intrafemoral injection of differentiated NHP-
iPSCs (Abed et al., 2015; Gori et al., 2015). Since our differ-
entiation system makes it feasible to produce large
numbers of CD34+CD45+ cells that are highly enriched in
myeloid and lymphoid progenitors, it opens opportunities
for preclinical testing of iPSC-derived blood products in a
highly relevant NHP model.
Moving artificial blood products into the clinic requires
proof-of-concept animal studies and preclinical safety
and toxicity assessment of stem cell therapies in animal
models before entering into clinical trials (FDA, 2008,
2013; Fink, 2009). Tumorigenicity, biodistribution, and
immunogenicity are identified as areas of concern that
need to be addressed through in vivo studies (Goldring
et al., 2011; Sharpe et al., 2012). The Food andDrug Admin-
istration (FDA) considers two types of animal models
acceptable for preclinical studies: evaluation of human
cells in an immune compromised animal host and evalua-
tion of analogous cells in a species-specific model (FDA,
2013). Both approaches have limitations for the assess-
ment of tumorigenicity and biodistribution because hu-
man cells may behave differently in an animal host
environment, and intrinsic differences could exist in cell
properties between human and animal cells. However,
analogous animal models would be a better predictor of
immunogenicity and immunotoxicity, because they
require immunocompetent hosts.45+ Hematopoietic Progenitors
on of myeloid, erythroid, and megakaryocytic cells from CD34+CD45+
.
erred on fresh OP9 cells, and cultured in differentiating medium with
show that all three NHP lines produce all types of myeloid cells,
), and megakaryocytes (Mk). Scale bar represents 100 mm. Bar graph
throid, megakaryocytic, and myeloid cells. Representative cytospins
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Although the FDA considers analogous cell product data
an acceptable option for preclinical studies, it requires
substantial similarity between analogous animal and
human products (FDA, 2013). Due to the significant
differences in the innate and adaptive immune system
(Mestas and Hughes, 2004), hematopoietic system ho-
meostasis, cell surface markers, and the requirements for
hematopoietic cell engraftment (Harding et al., 2013;
Trobridge and Kiem, 2010), rodent models are unlikely
to fulfill this FDA requirement. The NHP model will
be able to overcome these inherent limitations of rodent
models, especially limitations related to completely dif-
ferent structure and MHC binding specificity between
mouse and human KIRs (Natarajan et al., 2002; Parham
et al., 2010). Because tumorigenicity associated with cell
therapies may manifest several years after stem cell
injection (Amariglio et al., 2009), NHP models would
be critical in evaluating the long-term safety of stem
cell therapies. The utility of an NHP model for safety
evaluation can be appreciated from the lessons learned
from gene therapy studies. The assumption about
the safety of replication-incompetent retroviral vectors
for gene therapy made in small animal studies was
proved wrong in gene therapy trials targeting HSCs
in children with X-linked severe combined immunodefi-
ciency, who later developed vector-related leukemia
several years after treatment with retrovirally modified
stem cells (Hacein-Bey-Abina et al., 2003a, 2003b).
Evidence that such retroviral-mediated gene therapy
targeting HSCs can cause potential leukemia or
malignant transformation has subsequently emerged
from studies using NHPs (Seggewiss et al., 2006; Zhang
et al., 2008).
In summary, our studies generated transgene-free iPSCs
from various NHP species, and demonstrated the critical
role of GSK3b inhibition for establishing a reproducible
protocol for the efficient induction of mesoderm and mye-
lolymphoid hematopoietic cells from NHP-iPSCs. This
study lays the foundation for advancing an NHP model
for preclinical testing of iPSC-based therapies for blood
and immune system diseases.Figure 5. Lymphoid Potential of NHP-iPSC Hematopoietic Progen
(A) Schematic representation of protocol for lymphoid differentiation
(B) Flow cytometric profile of T cells generated after 3 weeks of cultu
(C) Analysis of RAG1, RAG2, and CD3E gene expression by qRT-PCR. Re
mean ± SE from at least three experiments.
(D) Analysis of TCR rearrangement by genomic PCR in T cells obtained f
agarose gel and visualized using ethidium bromide. PB is peripheral blo
from day-10 OP9 co-culture (negative control).
(E) Expression of CD56 and CD159a in NK differentiation cultures.
(F) Analysis of PRF1 and IFNG gene expression by qRT-PCR. Relative ex
from at least three experiments.
Stem CeEXPERIMENTAL PROCEDURES
Reprogramming NHP Fibroblast Cells
All animal procedures were approved by the University of Wiscon-
sin Medical School’s Animal Care and Use Committee. NHP
fibroblast cells were reprogrammed with combinations of oriP/
EBNA1-based episomal vectors described in Yu et al. (2009).
RhF5-iPS 19.1, Cy.F 3L iPS, and Cy0669 iPS #1 cells were generated
from fibroblasts isolated from a skin punch biopsies from a rhesus
monkey, Chinese cynomolgus monkey, and Mauritian cynomol-
gus monkey, respectively. RhF5 19.1 and Cy.F 3L were reprog-
rammed with episomal combination #19 (Yu et al., 2009) using
l-myc instead of c-myc. Cy0669 fibroblasts were reprogrammed
using episomal combination #6 (Yu et al., 2009). For each reprog-
ramming, 1–3 3 106 fibroblasts were transfected with 15 mg of
each plasmid using the electroporator (250 V, 1000 mF, N resis-
tance; Bio-Rad) and seeded onto MEFs in 10-cm dishes. Cells
were cultured in DMEM with 20% fetal bovine serum (FBS) and
non-essential amino acids for 4–5 days. Medium was changed
every 2 days. The cultures were split 1:3 if they became overconflu-
ent before the 4–5 days. The cultures were then switched to E7 +
sodium butyrate (DF3S with 100 ng/ml bFGF, 1.74 ng/ml trans-
forming growth factor b, 10.7 mg/ml transferrin, 10 mg/ml insulin,
and 0.1 mM sodium butyrate) until morphology changes began to
appear, at which point the medium was switched over to primate
iPSC medium (E8 with 100 ng/ml Nodal, 1.94 ng/ml glutathione,
13 Glutamax [Life Technologies], and 13 Chemically Defined
Lipid Concentrate [Life Technologies]). Colonies began to appear
within 3–4 weeks and were subsequently seeded onto MEF plates
for expansion and characterization.Teratoma Formation Assay
To test the developmental potential, NHP-iPSC lines were grown
on 10-cm plates until approximately 80% confluent. Cells were
then harvested with 0.5 mM EDTA and washed off the plate
using maintenance medium. For each 10-cm dish, cells were
resuspended in 400 ml of primate medium +220 ml of Matrigel.
Volumes of 300, 200, and 100 ml from each cell line were injected
into the hindlimb muscles of 6-week-old immunocompromised
SCID-beige mice. After 6–10 weeks, teratomas were dissected
and fixed in 4% paraformaldehyde. Samples were embedded in
paraffin and processed with H&E staining at the Histology Lab at
the School of Veterinary Medicine, University of Wisconsin-
Madison.itors Generated in Co-culture with OP9
.
re of CD34+CD45+ on OP9-DLL4 from the indicated NHP-iPSCs.
lative expression normalized to b-actin is shown. Error bars denote
rom the MnCy0669 iPS#1 line. The PCR products were resolved on 2%
od (positive control) and D10 CD45+ cells are floating cells collected
pression normalized to ACTB is shown. Error bars denote mean ± SE
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iPSC Differentiation in OP9 Co-culture
All iPSC lines were maintained in an undifferentiated state in
primate ESC medium (ReproCell, Japan) supplemented with
4ng/ml of FGF2 by passages on MEFs every 3 days. A mouse OP9
stromal cell line was kindly provided by Dr. Toru Nakano (Osaka
University). OP9 was maintained on gelatin-coated plastic in
a-minimal essential medium (aMEM; Gibco-Invitrogen) supple-
mented with 20% defined FBS (HyClone Laboratories).
iPSCs prepared in suspension of small cell aggregates were added
to OP9 cells in aMEM supplemented with 10% FBS (HyClone Lab-
oratories) and 50 mM b-mercaptoethanol. On day 1 of co-culture,
4 mM CHIR99021 (Tocris) and 50 ng/ml VEGF (Peprotech) were
added. The medium was changed on day 3 to fresh medium with
50 ng/ml VEGF. From day 6 of co-culture, a hematopoietic cyto-
kine cocktail consisting of 50 ng/ml SCF, 20 ng/ml TPO,
20 ng/ml IL-6, and 20 ng/ml IL-3 (Peprotech) was added to theme-
dium. iPSC/OP9 co-cultures were incubated for up to 10 days under
standard conditions (37C, 5% CO2, R95% humidity). Half the
mediumwas replacedwith freshmediumon days 6 and 8. Floating
blood cells or total cultureswere collected for analysis. For total cul-
ture harvesting, hESC/OP9 co-cultures were dispersed by succes-
sive enzymatic treatment with collagenase IV (Gibco-Invitrogen;
1 mg/ml) for 20 min at 37C, and 0.05% trypsin/0.5 mM EDTA
(Gibco-Invitrogen) for 15 min at 37C. Cells were resuspended
by pipetting, washed twice with PBS containing 5% FBS, filtered
through a 70-mm cell strainer (Becton Dickinson), and used for
downstream analysis. For mesoderm induction, day-4 differenti-
ated cells were analyzed by flow cytometry for expression of
APLNR. RNA was isolated from day-4 differentiated cells after
depleting OP9, cDNA was transcribed, and the relative expression
of mesoderm genes KDR and T were analyzed by qRT-PCR.
Secondary Co-culture
For secondary co-culture, floating cells from day-10 iPSC-OP9 co-
culture were harvested and 2 3 105 cells were seeded onto fresh
OP9 in differentiating medium in the presence of 50 ng/ml SCF,
20 ng/ml TPO, 20 ng/ml IL-3, 20 ng/ml IL-6, and 0.5 U/ml eryth-
ropoietin (R&D Systems). Floating cells were harvested after
3 days and analyzed by Wright-Giemsa staining. For myeloid
expansion, day-10 floating cells were recultured on fresh OP9
monolayer in differentiating medium with 100 ng/ml GM-CSF.
Flow cytometry was performed after 3 days. For erythroid differen-
tiation, day-10 floating cells were seeded onto fresh OP9 in differ-
entiatingmediumwith 50 ng/ml SCF, 20 ng/ml TPO, and 0.5 U/ml
erythropoietin for 7 days and analyzed by flow cytometry. For
megakaryocyte differentiation, day-10 floating CD34+CD45+ cells
were seeded onto ultralow attachment plates (Corning) in differen-
tiatingmedium containing 50 ng/ml SCF, 20 ng/ml TPO, 20 ng/ml
IL-3, 20 ng/ml IL-6, and 20 ng/ml IL-11.
Lymphoid Differentiation of Day-10 Cultures
The OP9 cell line expressing human DLL4 (OP9-DLL4) was estab-
lished by using lentivirus expressing human DLL4 under the
EF1a promoter. For T cell differentiation, the floating CD45+ cells
were collected from day-10 human PSC/OP9 co-culture, strained
through a 70-mm cell strainer (BD), resuspended in T cell differen-
tiation medium consisting of aMEM (Gibco) supplemented with254 Stem Cell Reports j Vol. 6 j 243–256 j February 9, 2016 j ª2016 The Au20% FBS (Hyclone), 5 ng/ml IL-7, 5 ng/ml Flt3 ligand, and
10 ng/ml SCF, and cultured on OP9-DLL4 for 3 weeks with weekly
passage. Floating cells were collected for flow analysis and genomic
DNA extraction for TCR rearrangement analysis using a TCR rear-
rangement kit (Invivoscribe Technologies). For NK cell differentia-
tion, floating CD45+ cells from iPSCs/OP9 co-culture were
collected on day 10 and then co-cultured on OP9-DLL4 in aMEM
containing 20% FBS, 20 ng/ml IL-7, 10 ng/ml Flt3 ligand, and
10 ng/ml IL-2 for up to 4 weeks at 37C and 5% CO2. Expression
of NK cell-specific markers were then analyzed by flow cytometry.Flow Cytometry
Cell surface staining was completed using antibodies that cross-
reacted with cynomolgus and rhesus monkey cells coupled with
7-aminoactinomycin D for dead cell exclusion. The antibodies
are listed in Table S1. Control staining with the appropriate iso-
type-matched mouse monoclonal antibody controls was included
to establish a threshold for positive staining and subset gating.
Samples were analyzed using a FACSCalibur flow cytometer (BD)
and FlowJo software (Tree Star).Colony Formation Assay
Cells were cultured in a 35-mm dish with 3 ml of enriched
MethoCult (H4435; StemCell Technologies) with high serum con-
centration for 10–14 days, and individual colonies were scored by
macroscopic morphology. Representative colonies were picked up
and analyzed by microscopic morphology after Wright-Giemsa
staining. In some experiments, the cells were cultured in serum-
free MethoCult (H4436; Stem Cell Technologies) supplemented
with either 10% or 15% FBS.Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
5 software. Data obtained from multiple experiments were re-
ported as the mean ± SE. Student’s t test and ANOVA were used
to compare between groups. Differences were considered signifi-
cant at p < 0.01.
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